ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery

Wang, Ting; Tang, Yuting; Pan, Wenjun; Yan, Botao; Hao, Yifan; Zeng, Yunli; Chen, Zexin; Lan, Jianqiang; Zhao, Shuhan; Deng, Chuxia; Zheng, Hang*; Yan, Jun*南方医科大学; 1
Diseases of the Colon and Rectum2023-5DOI: 10.1097/DCR.0000000000002511
2被引7阅读
引用收藏
分享

摘要

BACKGROUND: Recent studies have shown patient-derived tumor organoids can predict the drug response of patients with cancer. However, the prognostic value of patient-derived tumor organoid-based drug tests in predicting the progression-free survival of patients with stage IV colorectal cancer after surgery remains unknown. @@@ OBJECTIVE: This study aimed to explore the prognostic value of patient-derived tumor organoid-based drug tests in patients with stage IV colorectal cancer after surgery. DESIGN: Retrospective cohort study. @@@ SETTINGS: Surgical samples were obtained from patients with stage IV colorectal cancer at the Nanfang Hospital. @@@ PATIENTS: A total of 108 patients who underwent surgery with successful patient-derived tumor organoid culture and drug testing were recruited between June 2018 and June 2019. @@@ INTERVENTIONS: Patient-derived tumor organoid culture and chemotherapeutic drug testing. @@@ MAIN OUTCOMES MEASURES: Progression-free survival. @@@ RESULTS: According to the patient-derived tumor organoid-based drug test, 38 patients were drug sensitive and 76 patients were drug resistant. The median progression-free survival was 16.0 months in the drug-sensitive group and 9.0 months in the drug resistant group (p < 0.001). Multivariate analyses showed that drug resistance (HR, 3.38; 95% CI, 1.84-6.21; p < 0.001), right-sided colon (HR, 3.50; 95% CI, 1.71-7.15; p < 0.001), mucinous adenocarcinoma (HR, 2.47; 95% CI, 1.34-4.55; p = 0.004), and non-R0 resection (HR, 2.70; 95% CI, 1.61- 4.54; p < 0.001) were independent predictors of progression-free survival. The new patient-derived tumor organoid-based drug test model, which includes the patient-derived tumor organoid-based drug test, primary tumor location, histological type, and R0 resection, was more accurate than the traditional clinicopathological model in predicting progression-free survival (p = 0.001). @@@ LIMITATIONS: A single-center cohort study. @@@ CONCLUSIONS: Patient-derived tumor organoids can predict progression-free survival in patients with stage IV colorectal cancer after surgery. Patient-derived tumor organoid drug resistance is associated with shorter progression-free survival, and the addition of patient-derived tumor organoid drug tests to existing clinicopathological models improves the ability to predict progression-free survival.

学科与关键词

关键词
Drug testsPatient-derived tumor organoidPrognostic valueProgression-free survivalPredictive modelStage IV colorectal cancer
相关
加载中…
  • Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer A Blinded Study
    Wang, Ting; Pan, Wenjun; Zheng, Hang; Zheng, Hongping; Wang, Zhejun; Li, Jia J.; Deng, Chuxia; Yan, Jun*Diseases of the Colon and Rectum, 2021, 64(7): 833-850.被引 31
  • Use of patient-derived tumor organoid platform to predict the benefit of postoperative adjuvant chemotherapy for poor responders to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Xue, Weisong; Wang, Ting; Yao, Jiaxin; Wu, Wei; Chen, Dexin; Yan, Botao; Dong, Xiaoyu; Tang, Yuting; Zeng, Yunli; He, Yueyu; Cao, Peihua; Shao, Fangyuan; Huang, Wenhua*; Deng, Chuxia*; Yan, Jun*Bioengineering & Translational Medicine, 2023, 8(6): e10586.被引 1
  • Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapy
    Yao, Lei; Zao, Xiao-Long; Pan, Xiao-Fei; Zhang, Hao-Gang; Wang, Fu-Jing; Qiao, Peng-Fei*JOURNAL OF CHEMOTHERAPY, 2023, 35(2): 104-116.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Diseases of the Colon and Rectum
发表日期
2023-05
卷期
第 66 卷, 第 5 期
页码
733-743
DOI
10.1097/DCR.0000000000002511
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773117]; Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer [2020B121201004]; Special Fund for Guangdong Province Public Research and Capacity Building [2014B020215002]; Science and Technology Planning Project of Guangzhou City [202206010085]; Special Fund from Clinical Research of Wu Jieping Medical Foundation [320.2710.1851]; Clinical Research Project of Southern Medical University [LC2016PY010]; President Fund of Nanfang Hospital [2019Z023]; High-Level Research Matching Foundation of Nanfang Hospital [2014067]; Scientific Research Foundation for High-Level Talents in Nanfang Hospital of Southern Medical University [201404280056]; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation [pdjhb0100, pdjh2017a0093]; Training Program for Undergraduate ~Innovation and Entrepreneurship [201912121008, 202012121091]; Clinical Research Project of Nanfang Hospital [2018CR034, 2020CR001, 2020CR011]; China Postdoctoral Science Foundation [2020M682789]

作者

  • W

    Wang, Ting (第一作者)

    1 · southern med univ

  • T

    Tang, Yuting

    1 · southern med univ

查看全部 12 位作者收起作者
  • P

    Pan, Wenjun

    1 · southern med univ

  • Y

    Yan, Botao

    1 · southern med univ

  • H

    Hao, Yifan

    1 · southern med univ

  • Z

    Zeng, Yunli

    1 · southern med univ

  • C

    Chen, Zexin

  • L

    Lan, Jianqiang

  • Z

    Zhao, Shuhan

    1 · southern med univ

  • D

    Deng, Chuxia

  • Z

    Zheng, Hang (通讯)

    1 · southern med univ

  • Y

    Yan, Jun (通讯)

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417